Update: Iomab-B on track for Phase III
Actinium Pharmaceuticals has started production of clinical batches of Iomab-B ahead of initiating a pivotal Phase III study. Iomab-B, a beta radio-emitter, could start this trial, for use as a conditioning agent for hematopoietic stem cell transplantation (HSCT, bone marrow transplant) instead of chemotherapy and/or whole body radiation, in mid-15. Phase I/II results suggested the overall survival rate at one year of patients over 55 with AML could be increased from c 10% to c 30% with Iomab-B treatment.Actinium Pharmaceuticals is a clinical-stage, biopharmaceutical company focused on developing and potentially commercializing therapies for targeted conditioning prior to cell therapies. The company's key targeted conditioning product candidate is Iomab-B, an Antibody Radiation-Conjugates (ARC) that is comprised of the anti-CD45 mAb known as apamistamab or BC8 and the radioisotope iodine-131. The company is applying its CD33 targeting ARC product candidate lintuzumab-Ac-225 to multiple hematologic indications as CD33 is an antigen that has been found to be expressed in a majority of patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome and 25% to 35% of patients with Multiple Myeloma.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.